How to START? Four pillars to optimally begin your orphan drug development

https://link.springer.com/article/10.1186/s13023-023-02845-9 Virginie Hivert, our Therapeutic Development Director, was a co-author in a position paper published this month by the Orphanet Journal of Rare Diseases. The position paper, 'How to START? Four pillars to optimally begin your orphan drug development' details best practices for initiating the process of developing medicines to treat rare conditions. The paper proposes a 'START' checklist relating to key considerations when starting an orphan drug development: STakeholder mapping, Available information on the disease, Resources, and Target patient value profile.